ANALYSIS OF PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC PANCREATIC CANCER RECEIVING FIRST-LINE mFOLFIRINOX AT K HOSPITAL
.
.
Abstract
Objective: Evaluation of prognostic factors associated with survival outcomes in patients with metastatic pancreatic cancer receiving first-line mFOLFIRINOX.
Methods: A retrospective and prospective study on 36 patients diagnosed with metastatic pancreatic cancer at K Hospital were treated with the first-line mFOLFIRINOX regimen. The primary endpoints were overall survival (OS) and progression-free survival (PFS), with analyses of factors associated with OS and PFS. Secondary endpoints included response rate, treatment-related toxicity, and the rate of treatment interruption.
Results: The median follow-up was 15.6 months (95% CI, 3.8–27.3). The median progression-free survival was 6.7 months, and the median overall survival was 12.5 months. In univariate analysis, age <60 and ECOG performance status (PS) 0 were associated with prolonged progression-free survival (PFS) and overall survival (OS). ECOG PS 0 was identified as an independent prognostic factor for overall survival. The overall response rate (ORR) was 30.6 %, disease control rate (DCR) was 66.6%. Grade 3 or 4 toxicities were mainly hematologic, including neutropenia in 33.4% of patients and thrombocytopenia in 2.8%
Conclusion: The mFOLFIRINOX regimen demonstrated treatment efficacy. ECOG PS 0 was identified as favorable prognostic factors associated with prolonged survival in patients with metastatic pancreatic cancer.
.
Keywords
Pancreatic cancer, mFOLFIRINOX, chemotherapy, metastatic, prognostic factors.
[1] Nguyễn Bá Đức, Trần Văn Thuấn, Nguyễn Tuyết Mai. Ung thư tụy. Điều trị nội khoa bệnh ung thư. 2010, Nhà xuất bản y học, Việt Nam, 189–199.
[2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660.
[3] Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med 2011; 364: 1817–1825.
[4] Ozaka M, Ishii H, Sato T, et al. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2018; 81: 1017–1023.
[5] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J CANCER. Published online 2009:20.
[6] Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
[7] Ishii H, Okada S, Nose H, et al. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 1996; 12: 267–271.
[8] Yu KH, Ozer M, Cockrum P, et al. Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Cancer Med 2021; 10: 8934.
[9] Tas F, Sen F, Odabas H, et al. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 2013; 18: 839–846.
